Standard Biotools INC 8-K filings

Standard BioTools Inc. has filed an amendment to its Form 8-K, officially filing the Share and Asset Purchase Agreement for the sale of its mass cytometry business to Multiplex Bio Inc.

Standard BioTools Inc. announced the sale of its Mass Cytometry business to Multiplex Bio for up to $10 million and a $30 million buyout of contingent payments from Illumina, facilitating its merger with Treeline Biosciences.

Standard BioTools Inc. received a notification from Nasdaq indicating it does not meet the minimum bid price requirement for continued listing on the Global Select Market.

Standard BioTools Inc. and Treeline Biosciences, Inc. announced a definitive merger agreement, combining to form Treeline Biosciences, a public biopharma company focused on advancing Treeline's pipeline.

Standard BioTools Inc. has officially regained compliance with Nasdaq's minimum bid price requirement.

Standard BioTools Inc. announced a grant of 500,000 restricted stock units to Chief Business Officer Sean Mackay, with vesting scheduled over two years.

Standard BioTools reported first quarter 2026 revenue of $21.1 million, a 5% increase year-over-year, alongside a significant reduction in operating loss and adjusted EBITDA loss.

Standard BioTools Inc. has been notified by Nasdaq of non-compliance with the minimum $1.00 bid price requirement.

Standard BioTools Inc. announced better-than-expected fourth quarter and full year 2025 financial results, driven by cost savings and a strong cash position for future growth.

Standard BioTools Inc. filed an amended 8-K to provide pro forma financial statements reflecting the completed sale of its SomaLogic business to Illumina for $363.7 million in net cash proceeds.

Standard BioTools Inc. has completed the sale of its SomaLogic business to Illumina for up to $425 million in cash plus royalties, significantly boosting its cash reserves for future M&A.

Standard BioTools Inc. announced preliminary unaudited revenue for Q4 and full year 2025, exceeding guidance and positioning for strategic M&A.

Standard BioTools Inc. reported Q3 2025 results, detailing a $40M cost savings plan and a $550M Illumina cash injection to fuel future M&A.

Standard BioTools Inc. announced a restructuring plan, including a 15% global workforce reduction, to improve operational efficiency and reduce costs.

Standard BioTools Inc. announced a strategic consolidation of its U.S. R&D operations into Singapore and a reduction-in-force to enhance efficiency and reduce costs.

Standard BioTools Inc. reported second quarter 2025 financial results, including a strategic sale of SomaLogic to Illumina for up to $425 million, positioning the company for inorganic growth and profitability.

Standard BioTools Inc. has approved substantial restricted stock unit retention awards for its CEO and CFO, alongside an increased bonus target for the CFO, aiming to secure key leadership.

Standard BioTools Inc. announced the strategic sale of its SomaLogic proteomics business to Illumina, Inc. for an upfront cash payment of $350 million and up to $75 million in earnout payments, aiming to simplify its operating structure and achieve adjusted EBITDA break-even.

Standard BioTools Inc. announced that its stockholders approved a significant increase in shares reserved for its equity incentive plan and re-elected two Class III directors at its 2025 Annual Meeting.

Standard BioTools announced its first quarter 2025 financial results, highlighting a reduction in operating loss and improved adjusted EBITDA despite a challenging market.

Standard BioTools announces its financial results for Q4 and the full year 2024, highlighting revenue, cost reductions, and a strong balance sheet.

Standard BioTools reports preliminary full-year 2024 revenue of approximately $174 million and outlines progress in cost reduction and strategic growth initiatives.

Standard BioTools Inc. announces the departure of Chief Commercial Officer Jeremy Davis, effective February 1, 2025, with a severance package detailed.

Standard BioTools has agreed to pay $890,000 in legal fees to settle a shareholder lawsuit related to disclosures made during the acquisition of SomaLogic.

Standard BioTools has appointed Alex Kim, previously Interim CFO and COO, as its full-time Chief Financial Officer, effective November 11, 2024, and will vacate the Chief Operating Officer position.

Standard BioTools announced its third quarter 2024 financial results, highlighting a 50% year-over-year improvement in adjusted EBITDA and a 35% improvement in net loss, while reaffirming its full-year revenue outlook.

Standard BioTools provided an investor update highlighting its strategic focus on proteomics and multi-omics platforms, along with financial targets and growth drivers.

Standard BioTools Inc. has approved a new 2024 Change of Control and Severance Plan, replacing the 2023 plan, to provide severance benefits to its executive leadership team under certain termination conditions.

Standard BioTools has announced the resignation of its CFO, Jeffrey Black, effective August 31, 2024, and the appointment of COO Alex Kim as interim CFO, while also naming Sean Mackay as Chief Business Officer.

Standard BioTools announced its second quarter 2024 financial results, highlighting revenue growth but also a revised full-year revenue outlook and some service contract delays.